You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 08/03/2015

Company Name Symbol %Change
Stock Investors Sell Off Shares of Sanofi-Aventis, Down 1.3%

Print Share

Dec 28, 2012 (Market movers via COMTEX) -- Sanofi-Aventis (NYSE:SNY) is one of today's notable stocks in decline, down 1.3% to $46.87. The Dow is down 0.3% to 13,060 and the S&P is currently down 0.2% to 1,415.

Sanofi-Aventis is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.

Over the past year, Sanofi-Aventis has traded in a range of $33.03 to $47.97 and is now at $46.87, 42% above that low. Over the past week, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.6%.

There is potential upside of 16.4% for shares of Sanofi-Aventis based on a current price of $46.87 and an average consensus analyst price target of $54.53. The stock should discover initial support at its 50-day moving average (MA) of $44.96 and subsequent support at its 200-day MA of $40.32.


Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit today.

Copyright, Comtex News Network, Inc. 2012

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.